BioCentury on BioBusiness, Strategy
Alexion will need 3 years to find out if Enobia compound matches Soliris
Ultra-rarified heir
By Michael Flanagan
Senior Writer
Published on Monday, January 2, 2012
Alexion Pharmaceuticals Inc. will have to wait three years to find out whether its
purchase of Enobia Pharma Inc. for $610 million up front will provide a
Soliris-like winner in ultra-Orphan metabolic bone diseases. Alexion hopes to
launch Enobia's asfotase alfa to treat hypophosphatasia in late 2014.
Since early 2009, Alexion's
market cap has tripled from just over $4 billion to more than $13 billion. The
driver has been Soliris, a humanized mAb targeting complement 5 (C5) that is
approved to treat a pair of ultra-Orphan indications -paroxysmal nocturnal
hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) - where
there are no therapeutic alternatives.
104 words displayed of 793 words total.
Get the Full Text...
All contents Copyright © 1993-2012 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Purchase This Article
Learn what you're missing.
Broaden your Knowledge Base
The BioCentury Publications Package provides the essential coverage and analysis required by global biopharma decision makers.
Take advantage of our free trials and discover why BioCentury is the choice of biopharma professionals around the globe.
Free Trials Begin the Week Following Sign-up
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your records.
close [ X ]